
Mito Introduces $249 Coronary Artery Calcium Scan Without Referral
Edited by Vita Solenne
Research & Biotech · Updated October 6, 2026
Mito has launched a coronary artery calcium (CAC) scan priced at $249, available without a doctor's referral. This non-invasive scan assesses heart health by measuring calcium buildup in the coronary arteries, which can indicate the risk of heart disease. The procedure is quick and requires the patient to hold their breath briefly during the scan.
Share this story
Why it matters
- ✓The CAC scan provides valuable insights into cardiovascular health, which is crucial for longevity and health optimization.
- ✓Early detection of calcium buildup can lead to preventive measures, potentially reducing the risk of heart disease.
- ✓Access to this scan without a referral may empower individuals to take proactive steps in managing their heart health.
Mito Introduces $249 Coronary Artery Calcium Scan Without Referral
Mito, a company focused on longevity and health optimization, has recently announced the availability of a coronary artery calcium (CAC) scan for $249, which can be accessed without the need for a doctor's referral. This innovative offering aims to enhance individual access to important cardiovascular health assessments.
What is a Coronary Artery Calcium Scan?
A coronary artery calcium scan is a non-invasive imaging test that measures the amount of calcium in the coronary arteries. Calcium buildup in these arteries can be an early indicator of coronary artery disease (CAD), which is a leading cause of heart attacks. The scan involves a simple procedure where patients are required to hold their breath for a few seconds while the imaging is conducted, and it does not involve needles or contrast agents, making it a straightforward experience for patients.
Why is the CAC Scan Important?
The primary purpose of the CAC scan is to provide insights into an individual's heart health. By quantifying the amount of calcium present in the coronary arteries, healthcare providers can better assess the risk of heart disease. This information is particularly valuable for those who may not exhibit obvious symptoms but are at risk due to factors such as family history, age, or lifestyle choices.
Implications for Longevity Enthusiasts
For individuals pursuing longevity and health optimization, understanding cardiovascular health is essential. Here are a few reasons why the CAC scan is significant:
- Early Detection: The scan can help identify individuals at risk for heart disease before symptoms arise, allowing for timely intervention and lifestyle changes.
- Informed Decision-Making: With access to this scan, individuals can make more informed decisions about their health, including dietary adjustments, exercise regimens, and other lifestyle modifications that can enhance heart health.
- Empowerment: The ability to access this scan without a referral empowers individuals to take charge of their health, encouraging proactive management of cardiovascular risks.
Cost and Accessibility
At a price point of $249, the CAC scan is positioned as an affordable option for those interested in monitoring their heart health. The removal of the referral requirement is a significant step towards increasing accessibility, allowing more people to take advantage of this important diagnostic tool.
Conclusion
Mito's introduction of the coronary artery calcium scan marks a notable advancement in the field of preventive health care. By providing an accessible and affordable means to assess heart health, Mito is enabling individuals to take proactive steps towards longevity and overall well-being. As heart disease remains a leading health concern, tools like the CAC scan can play a crucial role in early detection and prevention strategies, ultimately contributing to healthier, longer lives.
Sources
- Mito adds a $249 heart scan. Who needs one? — Longevity Technology
Newsletter
Your weekly longevity signal. No spam.
Comments
Log in with
Loading comments…
More in Biotech

Fractyl Revita Shows Promise in Reducing Weight Regain After GLP-1 Therapy
Fractyl Health has announced positive results from the REMAIN-1 pivotal study, which evaluated the…
Just now

Exploring the Connection Between Big Pharma and Gray-Market Peptides
A recent analysis reveals significant ties between the pharmaceutical industry and gray-market…
2d ago

Kailera Completes Enrollment for Obesity Trials, Results Expected in 2028
Kailera has completed enrollment for its three Phase 3 trials of ribupatide, a weekly injection…
2d ago

Longeveron’s Stem Cell Therapy Shows Promise for Reducing Brain Inflammation in Alzheimer’s Patients
Longeveron has released new preclinical data suggesting that its stem cell therapy may lead to…
2d ago